Caswell-Jin, Jennifer L. http://orcid.org/0000-0002-5711-8355
McNamara, Katherine http://orcid.org/0000-0002-3717-6494
Reiter, Johannes G. http://orcid.org/0000-0002-0170-7353
Sun, Ruping http://orcid.org/0000-0003-3702-9483
Hu, Zheng
Ma, Zhicheng
Ding, Jie
Suarez, Carlos J.
Tilk, Susanne
Raghavendra, Akshara
Forte, Victoria
Chin, Suet-Feung http://orcid.org/0000-0001-5697-1082
Bardwell, Helen
Provenzano, Elena
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Lang, Julie http://orcid.org/0000-0002-7534-6124
West, Robert
Tripathy, Debu http://orcid.org/0000-0002-5711-2404
Press, Michael F.
Curtis, Christina http://orcid.org/0000-0003-0166-3802
Article History
Received: 24 August 2018
Accepted: 18 January 2019
First Online: 8 February 2019
Change Date: 30 May 2019
Change Type: Correction
Change Details: The original version of this Article omitted from the Author Contributions statement that ‘R.S. and J.G.R contributed equally to this work.’ This has been corrected in both the PDF and HTML versions of the Article.
Competing interests
: J.L. reports research funds from ANGLE Parsortix and is a member of the speaker bureau of Genomic Health. M.F.P. holds consulting or advisory role with honoraria at Karyopharm Therapeutics, Puma Biotechnology, Biocartis, Eli Lilly & Company, Novartis Pharmaceuticals, F. Hoffmann La-Roche Ltd. C. Caldas is a Scientific Advisor to Astrazeneca-iMed and has received research funding from Astrazeneca, Servier, Genentech/Roche. M.F.P. has received research grants to his institution from: Cepheid, Eli Lilly & Company, Novartis Pharmaceuticals, F. Hoffmann La-Roche Ltd. C. Curtis is a Scientific Advisory Board member and shareholder of GRAIL and consultant for GRAIL and Genentech. The remaining authors declare no competing interests.